Patent: 10,071,992

Summary for Patent: 10,071,992

Title:	Diacylglycerol acyl transferase 2 inhibitors
Abstract:	Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Inventor(s):	Boehm; Markus (Mansfield, MA), Cabral; Shawn (Groton, CT), Dowling; Matthew S. (Old Lyme, CT), Futatsugi; Kentaro (Quincy, MA), Huard; Kim (Medford, MA), Lee; Esther Cheng Yin (Brookline, MA), Londregan; Allyn T. (Barrington, RI), Polivkova; Jana (Mystic, CT), Price; David A. (Concord, MA), Li; Qifang (Stonington, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	15/674,914
Patent Claims:	see list of patent claims

United States Patent 10,071,992: Claims Audit and US Landscape Assessment

What does US 10,071,992 actually claim?

US Patent 10,071,992 is organized around a broad Formula (I) chemical genus, supported by nested sub-genus/formula embodiments and then a set of specific exemplified compounds. The patent extends beyond composition-of-matter into formulation and therapeutic method claims focused on metabolic/liver indications.

Core structure: Formula (I) genus (Claim 1)

Claim 1 recites a compound of Formula (I) “wherein” multiple substitution variables are defined:

• D¹ and D²: each independently N or CH
• R¹: H or (C1–C2)alkyl, optionally substituted with one or two substituents selected from:
  • fluoro
  • (C3–C6)cycloalkyl
• R²: H or fluoro
• R³: defined as a substituent group (rendered in the claim text as an inserted structure)
• R⁴: H, cyano, or (C1–C4)alkyl, optionally substituted with one or two substituents selected from:
  • OH
  • –S(O)2R⁶ (sulfonyl/ sulfoxide-type motif depending on interpretation)
• R⁵: H or –OH
• R⁶: (C1–C4)alkyl
• Plus pharmaceutically acceptable salts

Claim scope implication: the claim is a classic genus: broad on ring/heteroatom positioning (D¹/D²) and substituent permissiveness (fluoro, OH, sulfonyl motifs). The main narrowing is carried by the definitions of R³ and the specific embodiment patterns later.

Sub-genus and structure-specific claims

Claims 2–7 narrow within Formula (I) by selecting specific named formulas and variable constraints:

• Claim 2: Formula (Ia) embodiment within Claim 1
• Claims 3–4: further constraint of R³ (two distinct R³ instantiations)
• Claims 5–6: R¹ = methyl, applied to Claims 3–4
• Claim 7: applies to Claim 6 and limits R⁴ to H, –CH2OH, or cyano

These are not merely dependent claims; they function as distinct claim fallbacks to protect against design-around that changes one or more variables without leaving the general scaffold.

Exemplified compounds: dense coverage (Claims 8–10)

The patent then asserts explicit compound identities with extensive stereochemical specification and alternative N-substitution patterns.

• Claim 8 lists a long set of specific compounds (with stereochemistry and side-chain diversity), plus salts.
• Claim 9 provides a shorter subset focused on tetrahydrofuran (THF) substituted N analogs with specified R/S stereochemistry.
• Claim 10 claims a compound having a specific drawn structure (structure provided in the text as an inserted formula image).

Scope implication: these explicit compounds improve enforceability because they reduce reliance on claim construction disputes over Formula (I) boundaries. They also improve validity posture because experimental compounds can support enablement and written description if the specification matches.

Formulation claims (Claims 11–14)

• Claim 11: a pharmaceutical composition with the Claim 1 compound (or salt), therapeutically effective amount, plus at least one excipient.
• Claim 12: adds at least one additional pharmaceutical agent selected from:
  • anti-inflammatory
  • anti-diabetic
  • cholesterol/lipid modulating agent
• Claim 13: further narrows those additional agents by listing a large portfolio (ACC inhibitors, DGAT-1, PDE-10, AMPK activators, incretin drugs, PTP-1B inhibitors, SGLT2 inhibitors, statins, PCSK9 modulators, etc.).
• Claim 14: extends again with a different catalog (cysteamine/cystamine, antioxidants, CB1 modulators, PPAR activity regulators, benzothiazepines, RNA antisense to PTPRU, GLATIRAMER acetate, pentraxin proteins, etc.), plus combinations.

Landscape implication: these combination-formulation claims can be attacked as overly broad if they do not establish a clear technical contribution over known combination therapies for metabolic disease. They also raise infringement complexity: proving “at least one additional agent” plus excipient and dosage form is fact-specific.

More specific compound claim set (Claims 15–17)

• Claim 15: a specific THF-containing compound:
  “2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide” (plus salt)
• Claim 16: exact identity to claim 15, without salt language in the provided text (then salts elsewhere depending on standard phrasing)
• Claim 17: another drawn structure (inserted formula)

Crystal/polymorph claims (Claims 18–20)

• Claim 18: a crystal comprising a compound having a specified structure.
• Claim 19: powder X-ray diffraction (PXRD) peaks at 2θ = 5.3 ± 0.2, 7.7 ± 0.2, 15.4 ± 0.2 (Cu Kα, 1.54056 Å).
• Claim 20: PXRD peaks at 2θ = 6.5 ± 0.2, 9.3 ± 0.2, 13.6 ± 0.2.

Critical enforcement implication: polymorph claims can create strong leverage if the accused product uses the same solid form and can be matched to those PXRD peak sets. They can also become fragile if the accused solid is a different polymorph or if peak calibration/measurement conditions differ.

Methods of treatment: fatty liver and related endpoints (Claims 21–24)

• Claim 21: method of treating fatty liver, NAFLD, NASH, NASH with fibrosis, NASH with cirrhosis, and NASH with cirrhosis and hepatocellular carcinoma in humans by administering a therapeutically effective amount of Claim 1 compound or salt.
• Claim 22: method with two separate pharmaceutical compositions:
  • first composition is per Claim 12
  • second composition includes “at least one additional pharmaceutical agent” from the same anti-inflammatory/anti-diabetic/cholesterol/lipid modulation categories
• Claim 23: simultaneous administration
• Claim 24: sequential administration in any order

Landscape implication: method claims on NAFLD/NASH are high-stakes because they target a commercially active category. But they are also vulnerable to prior art on: 1) known metabolic/liver compounds, 2) general use of similar mechanisms, and 3) combination therapy rationales.

Which claim elements are most likely to drive infringement disputes?

1) Claim construction on Formula (I) variables

The breadth hinges on definitions of R³, plus D¹/D² placement and substituent optionality. In litigation, disputes typically focus on whether an accused structure satisfies the exact mapping of each variable, especially where the claim text includes inserted structural moieties.

2) Stereochemistry and specific side-chain identity

Claims 8 and 9 explicitly enumerate (S) and (R) versions. If an accused product is enantiomerically enriched in the opposite stereoisomer, infringement turns on whether the claims are limited to the named stereoisomer or cover mixtures.

3) Salt coverage

Nearly all claims include “pharmaceutically acceptable salt thereof.” If the competitor markets a freebase rather than a salt, infringement depends on how the patent specification defines salt forms and whether the administered form is a salt.

4) Solid-form matching for polymorph claims

Claims 18–20 are constrained by specific PXRD peak positions. Even small differences in crystal form can defeat those claims. Measurement conditions (instrument, reference material, sample preparation) can become central.

5) Combination method/formulation proof burdens

Claims 12–14 and method claims 22–24 require demonstrating inclusion of additional therapeutic agents and the composition architecture. This raises evidentiary burden in enforcement and in patent challenges.

How strong is the claim architecture as a “validity and enforceability ladder”?

Strengths

• Genus + sub-genus + exemplified compounds: This reduces the risk that a single claim fails entirely.
• Multiple independent hooks: composition-of-matter (Claim 1), formulation (Claims 11–14), solid form (Claims 18–20), and therapeutic use (Claims 21–24).
• Fallback narrowing within the genus: Claims 2–7 act as targeted backstops.
• Crystallinity specificity: PXRD-defined crystals provide a concrete technical criterion.

Critical vulnerabilities

• Very broad “additional agent” menus: Claims 12–14 include large therapy categories (incretins, statins, PCSK9 modulators, etc.). This breadth can be attacked on enablement/written description and on non-obviousness, depending on the specification’s support for each combination.
• Method claims may overlap prior art use theories: NAFLD/NASH treatment by administering a compound of Formula (I) is likely to face obviousness challenges if the scaffold or mechanism was known for related metabolic disease endpoints.
• Crystal claims depend on disclosure alignment: If the specification does not clearly tie the PXRD patterns to specific compounds or to reproducible preparation methods, polymorph claims can be weakened.

Patent landscape analysis: where this filing likely sits

A complete “critical analysis of the claims and the patent landscape” for US 10,071,992 requires knowing:

• the patent’s priority dates,
• the assignee/applicant,
• related family members (WO/EP/JP),
• the specification content (mechanism, examples, solid form preparation, and biological data),
• and the exact claim set as granted vs. amended across prosecution.

Those inputs are not included in the provided material. Without them, any mapping to specific prior patents, competitor families, or prosecution history would be incomplete and potentially inaccurate.

Within the information given, the landscape contours are still inferable at the level of claim type competition:

• Composition-of-matter genus claims typically face heavy prior art around heteroaromatic substituted pyrimidine carboxamides and related kinase/pathway inhibitors for metabolic disease.
• Polymorph claims usually face direct competition only if the competitor uses the same solid form or if later-developed forms converge on identical PXRD peak sets.
• Method of treatment claims face broader prior art risk because NAFLD/NASH indications are crowded and often support broad obviousness combinations.
• Combination therapy claims create landscape exposure because many companies file “adjunct therapy” formulations with sweeping agent lists.

Business implications for enforcement and R&D

Infringement strategy: where to look first

• Check accused products against Claim 1 variable space: D¹/D² and R¹/R²/R⁴ substitution patterns.
• Confirm stereochemical identity for Claim 8/9 coverage.
• If the product is marketed as a solid form, demand PXRD of the drug substance and compare to Claim 19 and Claim 20 peak sets.
• If the product is a fixed combination or co-admin, verify whether the co-admin agent falls within Claims 12–14 enumerations and whether both compositions align with Claim 22’s architecture.

R&D strategy: design-around and portfolio

• Changing sensitive variables targeted by dependent claims (for example, R¹ = methyl and R⁴ in Claims 5–7; or the THF/side-chain identity in Claims 9/15/16) is likely to be more impactful than changing peripheral excipients.
• If the company has solid-form freedom, polymorph claims can be engineered around by using a different solid form than the one defined by the specific PXRD sets.

Key Takeaways

• US 10,071,992 is built on a Formula (I) genus with nested narrowing and a large set of explicit compound claims, then expands into formulation, crystal/PXRD, and NAFLD/NASH method-of-treatment claims.
• The most likely infringement pressure points are Formula variable mapping (especially R³), stereochemistry, salt vs freebase, and PXRD-matched solid form for Claims 18–20.
• The biggest patentability risk zone is the very broad “additional pharmaceutical agent” lists in Claims 12–14 and the resultant breadth of combination method claims (Claims 22–24).
• Without prosecution and family data, the landscape can only be assessed structurally; a complete prior-art and competitor map cannot be produced from the claim text alone.

FAQs

1. Is US 10,071,992 primarily a compound patent or a use patent?
   It is primarily a compound and solid-form patent (Claims 1, 18–20), with significant formulation (Claims 11–14) and method-of-treatment (Claims 21–24) coverage.

2. Do Claims 18–20 cover specific polymorphs?
   Yes. They are limited by PXRD peak 2θ ranges (Cu Kα, 1.54056 Å) using two different peak sets.

3. Can a competitor avoid infringement by changing only stereochemistry?
   Potentially, because Claims 8 and 9 expressly enumerate (R) and (S) versions. Coverage depends on whether the claims are strictly limited to those stereoisomers.

4. Do the combination claims require a fixed-dose product?
   Not necessarily. Claim 22 covers administering two separate compositions, with simultaneous or sequential administration in Claims 23–24.

5. Which part is most likely to be litigated first in a design-around?
   The Formula (I) substitution variables driving whether an accused compound falls within Claim 1, followed by PXRD matching if a specific crystal form is asserted.

---

References

[1] United States Patent 10,071,992 (claim text provided in prompt).

Details for Patent 10,071,992

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	April 15, 2014		2037-08-11
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 18, 2014		2037-08-11
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 04, 2020		2037-08-11
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	July 27, 2016		2037-08-11